Wasn't this trial designed by BP ? Thought it was mentioned in conference call earlier in year. Sounds like the triple crown is still in play , 2018 going to be a very interesting year. No need to let me know that is what we said last year. Major progress made in past year.
Correct, the PR states they have evidence K has the same effect on OC tumors as what was shown in pre-clinical studies, and that means it's highly effective! Dr B said the many months ago this trial was designed after consulting with big pharma because they wanted to see direct evidence that K modulates P53 activity.
News 
Market Data 
Discover 
